09:01 AM EDT, 05/30/2024 (MT Newswires) -- Candel Therapeutics ( CADL ) said Thursday that the US Food and Drug Administration has granted orphan drug designation to CAN-3110 to treat recurrent high-grade glioma.

"The orphan drug designation for CAN-3110 further reinforces the potential of this therapy and underscores the urgent need for novel and effective treatments for patients with rHGG," Chief Executive Paul Peter Tak said in a statement.

The FDA previously granted CAN-3110 fast-track designation to treat rHGG.

Shares of Candel Therapeutics ( CADL ) were up more than 5% in recent premarket activity.

Price: 9.38, Change: +0.59, Percent Change: +6.69